New Market Research Report: Type 2 Diabetes Therapeutics in Asia

GBI Research, the leading business intelligence provider, has released its latest research, "Type 2 Diabetes Therapeutics in Asia-Pacific Markets to 2020 - Increasing Uptake of Novel Drug Classes to Drive Market Growth", which provides insights into type 2 diabetes in the Asia-Pacific (APAC) markets of China, India, Japan and Australia. The report estimates the market size for 2013 and provides a forecast until 2020, and covers disease epidemiology, treatment algorithms, and treatment use patterns. It also provides in-depth analysis of the pipeline molecules, clinical trial failure rates, and recent deals. The report has been built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis carried out by GBI Research's team of industry experts.

Full Report Details at
- http://www.fastmr.com/prod/924460_type_2_diabetes_therapeutics_in_asiapacific.aspx?afid=301

In 2013, the value of the type 2 diabetes therapeutics market in APAC countries was an estimated $6.5 billion, and it is forecast to grow at a Compound Annual Growth Rate (CAGR) of 7.1% between 2013 and 2020 to $10.5 billion. This strong growth is due to the anticipated approval of products in relatively novel treatment classes, such as Glucagon-Like Peptide-1 (GLP-1) agonists, Dipeptidyl Peptidase-4 (DPP-4) inhibitors, and Sodium Glucose Transporter-2 (SGLT-2) inhibitors, as well as the growth of the prevalence population in the APAC region, particularly in India and China.

Scope

The report analyzes the treatment use patterns, market characterization, pipeline analysis and key licensing and co-development deals of the type 2 diabetes in the APAC markets of China, India, Japan, and Australia.It includes -

* A brief introduction to type 2 diabetes, including its pathophysiology, etiology, diagnosis and treatment algorithms
* In-depth analysis of currently marketed drugs for type 2 diabetes, including analysis of their safety, efficacy, treatment patterns, and strengths and weaknesses, as well as a heat map comparing them in terms of safety and efficacy
* A comprehensive review of the pipeline for type 2 diabetes, including individual analysis of a number of late-stage pipeline drugs that are likely to enter the market during the forecast period; the pipeline is analyzed by Phase distribution, molecule type, program type, mechanism of action and molecular target
* Additional in-depth analysis of pipeline drug clinical trials by Phase, trial size, trial duration and program failure rate for each molecule type
* Multi-scenario market forecast data to 2020, taking into account how the market might be affected by the introduction of new drugs, the expiry of key patents on current drugs, and the changes in disease epidemiology across the key developed markets
* Discussion of the drivers of and barriers to market growth
* In-depth analysis of all licensing and co-development deals that have occurred in the type 2 diabetes market since 2006

Reasons to Get this Report

About Fast Market Research

Fast Market Research is a leading distributor of market research and business information. Representing the world's top research publishers and analysts, we provide quick and easy access to the best competitive intelligence available. Our unbiased, expert staff is always available to help you find the right research to fit your requirements and your budget.

For more information about these or related research reports, please visit our website at http://www.fastmr.com or call us at 1.800.844.8156.

You may also be interested in these related reports:

- Systemic Psoriasis Therapeutics in Major Developed Markets to 2020 - Continued Uptake of Biologics and Novel Pipeline Drugs to Drive Growth
- Acute Myeloid Leukemia Therapeutics Market to 2020 - Novel Therapies to Offer Clinical Benefit in Small Patient Cohorts
- Colorectal Cancer Therapeutics in Asia-Pacific Markets to 2020 - Improved Regional Healthcare Access to Drive Uptake of High-Cost Targeted Therapies
- Melanoma Therapeutics Market to 2020 - Rising Prevalence and Evolving Treatment Algorithms to Drive Market Growth
- Glioblastoma Multiforme Therapeutics in Asia-Pacific Markets to 2020 - Novel Therapeutic Approaches Target High Unmet Need in Newly Diagnosed and Recurrent GBM